Greenbrook TMS
Greenbrook TMS provides FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy and FDA-approved Nasal Esketamine for treating Major Depressive Disorder and other mental health conditions, operating 183 treatment centers across the United States.
Services
Greenbrook TMS specializes in providing Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive treatment for Major Depressive Disorder and other mental health conditions. Additionally, the company offers Nasal Esketamine, an FDA-approved, ketamine-based antidepressant. TMS therapy is available at 183 treatment centers across the United States and is covered by most major insurance companies, including Medicare and Medicaid.
History
Greenbrook TMS has delivered over one million TMS treatments to more than 27,000 patients. The company is proactive in supporting mental health awareness and suicide prevention through collaborations with organizations such as the American Foundation for Suicide Prevention and This Is My Brave. To ensure patient safety, comprehensive COVID-19 safety measures have been implemented at all treatment centers.
Treatment Process
TMS therapy sessions at Greenbrook TMS typically last 18-20 minutes and are conducted in private centers. The therapy is non-invasive, has no drug-related side effects, and allows patients to drive themselves to and from treatments without any downtime. Greenbrook TMS offers free consultations and assists with insurance paperwork to determine patient eligibility. Third-party financing options are also available.
Patient Support and Resources
Greenbrook TMS has a dedicated Care Team that includes providers, patient consultants, and TMS technicians who support patients throughout their treatment journey. The organization also offers a 6-question quiz to help potential patients determine if TMS therapy could be beneficial for them. Additionally, Greenbrook TMS maintains a COVID-19 Resource Center to provide mental health support during the pandemic.
Financial Information
Greenbrook TMS has raised US$2.0 million in debt financing and completed a non-brokered private placement for aggregate gross proceeds of approximately US$6.25 million. The funds are likely used to expand their reach and improve services to better support patients seeking mental health treatment.